14 February 2024: Aker BioMarine ASA ("Aker BioMarine" or "the company") reports
revenues of USD 82.9 million, up from USD 79.0 million last year. Adjusted
EBITDA was USD 17.6 million, down from USD 20.7 million same quarter last year. 

Highlights fourth quarter:
- A year of strong revenue growth 
   - Fourth quarter revenues of USD 82.9 million, up 5% YoY
   - 2023 revenues of USD 335.2 million, up 21% YoY
- Ingredients EBITDA adj. of USD 19.3 million (USD 16.2 million )
- Brands EBITDA adj of USD -0.1 million (USD 2.2 million)
- Group EBITDA of USD 17.6 million (USD 20.7 million)
- Offshore production impacted by few harvesting days
   - Extended shipyard time for two vessels undergoing five-year class audit
   - 50,650 MT for the full year, 3% below 2022 
- USV successfully deployed at harvesting grounds early January

"Aker BioMarine delivered the highest organic growth in the history of the
company in 2023, with an impressive 21% revenue growth. This includes strong
performance across Qrill, Superba and Lang businesses. Group margins have
through the year been impacted by higher fuel prices and lower Superba
production. Ramping up Houston production of krill oil to normal capacity and
increasing Qrill prices will be supportive of margins going forward.", said
Matts Johansen, CEO of Aker BioMarine.

Outlook

Feed Ingredients
- Qrill Aqua's prices expected to benefit from a favourable marine ingredient
market. Contracted sales of raw materials to Human Health Ingredients at premium
prices will impact the product mix positively. 
- Over time, offshore production is expected to exceed 60,000 MT with the USV
drone now deployed 
- YTD 13 February production at 11,450 MT, 15% higher than  same period last
year.

Human Health Ingredients
- Superba sales is expected to grow across most sales regions at stable prices
only affected by product mix. Several Asian markets are expected to demonstrate
high annual sales growth over the next years.
- Based on increased Superba sales, the production at the Houston facility will
ramp up and  drive a gradual margin improvement throughout the year with full
effect expected from 2025 onwards.

Consumer Health Products: 
- Growth will be driven by private label product innovation across the major US
retailers. New product categories and new retailers are key drivers for future
growth.

Investments
- All major capital projects completed, and 2024 capital expenditures will be
related to maintenance and smaller improvement projects totaling USD 15-20
million.

At 09:00 CET today, the management hosts a webcast. Following the presentation,
there will be a Q&A session, where written questions can be submitted to
ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that
is available at www.akerbiomarine.com/investor. 

A replay of the presentation and Q&A session material will be made available
soon after the presentation at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.